healthcare

Penumbra's aspiration-based mechanical thrombectomy devices are building one of the most defensible competitive moats in medical technology

In a sector where utilisation and reimbursement are tightly linked, reduction in admin drag supports more stable, visible revenue streams.

In a world defined by macroeconomic uncertainty and shifting geopolitical realities, Pella continues to find opportunities.

Despite growing policy uncertainty, plenty of healthcare companies have managed to put up big returns, thanks to these qualities.

The next beneficiaries of the AI boom may not just be leaders like Nvidia. Global X’s Billy Leung discusses the next wave of winners.

Despite a five-fold share price increase, this US micro cap is still a bargain.

Platinum Asset Management’s Dr Bianca Ogden and KP Rx’s Hashan de Silva share their latest investments.

Antipodes Healthcare Portfolio Manager, Nick Cameron, outlines the investment case for pharmaceutical and medical device company, Alcon AG.

Telix smashes revenue forecasts with $1.2B+ guidance, but RFK Jr. & U.S. regulatory chaos pose risks. Shane Fitzgerald remains bullish.

Despite sky-high valuations, Jun Bei Liu is bullish on Pro Medicus. She first bought at $25 - now it’s 10x’d. How much higher can it climb?

Plasma is still a winner for the healthcare giant, but vaccinations face hurdles.

This commercial med-tech is valued at just ~A$40m despite having innovative tech, market adoption and a partnership with a global giant.

Could this Australian-American healthcare stalwart hit $60/share?

Real Asset Management's Matthew Strotton is bullish on this often overlooked area of healthcare real estate investing.

In this wire, we explain why one of our flagship funds shifted to a full-time healthcare focus.

Despite pressure on consumer spending, consumers prioritise trusted brands for their health-related needs and Haleon is a beneficiary.

Wilson Asset Management’s Dania Zinurova explains the big themes she chases for WAM Alternative Assets through her investments.

The Pharma & Biotech market had a relatively positive month with 41.5% of the coverage universe posting positive share price movements for the month of September. Over...

Why the healthcare sector could gain momentum even as economic growth potentially slows and the U.S. readies for a presidential election.

With volatility persisting investors may want to consider this defensive sector, supported by valuations and long-term growth drivers.